Children shouldn't receive the Moderna or Pfizer-BioNTech vaccines if they've had a severe allergic reaction to the ...

Recent health news highlights include FDA approval for a Johnson & Johnson heart device, Canada's approval of Moderna's RSV ...

Moderna reported better third-quarter results than expected Thursday morning, as the vaccine maker reported a surprise profit for the period amid its efforts to cut costs and $1.8 billion in sales of ...

Moderna earned $5.4 billion in U.S. revenues in 2021 and $4.4 billion in 2022 from COVID-19 vaccine sales. Northwestern University’s nanotechnology research institute, IIN, has supported over $2 ...

This time, we have GSK (GSK) "GSK" filing a lawsuit against Moderna (NASDAQ:MRNA) accusing them of patent infringement on their lipid nanoparticle (LNP) technology, which is used in mRNA therapeutics.

Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...

Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker ...

Oct 16 (Reuters) - Moderna (MRNA.O), opens new tab was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused the company of misusing the ...

Barclays lowered the firm’s price target on Moderna (MRNA) to $111 from $125 and keeps an Overweight rating on the shares. The company’s Q3 SpikeVax revenue beat estimates and guidance was ...

Tyler Van Buren’s rating is based on several factors influencing Moderna’s financial outlook. The analyst has adjusted the company’s expense projections downward, reflecting a more ...

Cost of sales dropped 77% thanks to well-managed costs and strategic pivots. Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related ...